Case Series: Clinical Characteristics of Cold Agglutinin Disease
A team of investigators identified a wide range of clinical behaviors in cold agglutinin disease, presented at the EHA25 Virtual Conference.
A team of investigators identified a wide range of clinical behaviors in cold agglutinin disease, presented at the EHA25 Virtual Conference.
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.